Gene ther­a­py tri­al is de­railed af­ter get­ting hit by the lat­est se­ri­ous ad­verse event in the field — shares crash

You can rack up an­oth­er se­ri­ous safe­ty con­cern flagged by a gene ther­a­py de­vel­op­er.

To­day it’s Ad­verum, which is re­port­ing that a pa­tient who re­ceived a high dose of their gene ther­a­py for di­a­bet­ic mac­u­lar ede­ma ex­pe­ri­enced a loss of vi­sion in a treat­ed eye. The pa­tient was giv­en a high dose (6 x 10^11 vg/eye) of AD­VM-022, with a case of hy­potony de­vel­op­ing, char­ac­ter­ized by a de­crease in oc­u­lar pres­sure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER